{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:14:59Z","timestamp":1790673299320,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00083"],"award-info":[{"award-number":["PI17\/00083"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/01810"],"award-info":[{"award-number":["PI15\/01810"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"REUNINVES"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients with respect to controls and whether these changes were associated with disease-related data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The multivariable analysis adjusted for demographic characteristics, cardiovascular risk factors, and lipid-related molecules showed that total cholesterol (beta coefficient: \u2212\u200922 [95%CI \u2013\u00a037 to \u2013\u00a07],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), triglycerides (beta coefficient: 24 [95%CI 2\u201347],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033), lipoprotein A (beta coefficient: 22 [95%CI 2\u201343],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033), and CEC (beta coefficient: \u2013\u00a06 [95%CI \u2212\u200910 to \u2013\u00a02]%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) were significantly different between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: \u2013\u00a00.21 [95%CI \u2013\u00a00.37 to \u2013\u00a00.05]%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) after multivariable adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02443-9","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T01:10:05Z","timestamp":1614042605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"Delgado-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Hern\u00e1ndez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiurma","family":"S\u00e1nchez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"de Armas-Rillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Armas-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 David","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-9295","authenticated-orcid":false,"given":"Federico","family":"Diaz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"2443_CR1","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","volume":"125","author":"RS Rosenson","year":"2012","unstructured":"Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905\u201319.","journal-title":"Circulation."},{"key":"2443_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2796.2007.01898.x","volume":"263","author":"AR Tall","year":"2008","unstructured":"Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263:256\u201373.","journal-title":"J Intern Med"},{"key":"2443_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127\u201335.","journal-title":"N Engl J Med"},{"key":"2443_CR4","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383\u201393.","journal-title":"N Engl J Med"},{"key":"2443_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/annrheumdis-2012-202914","volume":"73","author":"N Ronda","year":"2014","unstructured":"Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2014;73:609\u201315.","journal-title":"Ann Rheum Dis"},{"key":"2443_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13075-017-1311-3","volume":"19","author":"B Tejera-Segura","year":"2017","unstructured":"Tejera-Segura B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, Garcia-Dopico JA, Olmos JM, et al. HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther. 2017;19:113.","journal-title":"Arthritis Res Ther."},{"key":"2443_CR7","doi-asserted-by":"crossref","unstructured":"Sanchez-Perez H, Quevedo-Abeledo JC, de Armas-Rillo L, Rua-Figueroa I, Tejera-Segura B, Armas-Gonzalez E, et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatology (Oxford). 2020;19:113\u201323.","DOI":"10.1093\/rheumatology\/keaa038"},{"key":"2443_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00296-016-3530-3","volume":"37","author":"A Psarras","year":"2017","unstructured":"Psarras A, Soulaidopoulos S, Garyfallos A, Kitas G, Dimitroulas T. A critical view on cardiovascular risk in systemic sclerosis. Rheumatol Int. 2017;37:85\u201395.","journal-title":"Rheumatol Int"},{"key":"2443_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2012-202007","volume":"72","author":"A Man","year":"2013","unstructured":"Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72:1188\u201393.","journal-title":"Ann Rheum Dis"},{"key":"2443_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00296-004-0580-8","volume":"25","author":"EF Borba","year":"2005","unstructured":"Borba EF, Borges CT, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatol Int. 2005;25:379\u201383.","journal-title":"Rheumatol Int"},{"key":"2443_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/03009741003605648","volume":"39","author":"N Tsifetaki","year":"2010","unstructured":"Tsifetaki N, Georgiadis AN, Alamanos Y, Fanis S, Argyropoulou MI, Drosos AA. Subclinical atherosclerosis in scleroderma patients. Scand J Rheumatol. 2010;39:326\u20139.","journal-title":"Scand J Rheumatol"},{"key":"2443_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cca.2005.07.015","volume":"364","author":"G Lippi","year":"2006","unstructured":"Lippi G, Caramaschi P, Montagnana M, Salvagno GL, Volpe A, Guidi G. Lipoprotein [a] and the lipid profile in patients with systemic sclerosis. Clin Chim Acta. 2006;364:345\u20138.","journal-title":"Clin Chim Acta"},{"key":"2443_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"2443_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2:11\u20138.","journal-title":"J Scleroderma Relat Disord"},{"key":"2443_CR15","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1136\/annrheumdis-2013-204933","volume":"73","author":"MA Gonzalez-Gay","year":"2014","unstructured":"Gonzalez-Gay MA, Gonzalez-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis. 2014;73:1281\u20133.","journal-title":"Ann Rheum Dis"},{"key":"2443_CR16","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3899\/jrheum.121507","volume":"40","author":"I Ferraz-Amaro","year":"2013","unstructured":"Ferraz-Amaro I, Gonzalez-Gay MA, Garcia-Dopico JA, Diaz-Gonzalez F. Cholesteryl ester transfer protein in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1040\u20137.","journal-title":"J Rheumatol"},{"key":"2443_CR17","first-page":"1013","volume":"34","author":"I Ferraz-Amaro","year":"2016","unstructured":"Ferraz-Amaro I, Lopez-Mejias R, Ubilla B, Genre F, Tejera-Segura B, de Vera-Gonzalez AM, et al. Proprotein convertase subtilisin\/kexin type 9 in rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:1013\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"2443_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12026-016-8892-9","volume":"65","author":"MZ Szabo","year":"2017","unstructured":"Szabo MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65:543\u201350.","journal-title":"Immunol Res"},{"key":"2443_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013405","volume":"8","author":"SA Butt","year":"2019","unstructured":"Butt SA, Jeppesen JL, Torp-Pedersen C, Sam F, Gislason GH, Jacobsen S, et al. Cardiovascular manifestations of systemic sclerosis: a Danish nationwide cohort study. J Am Heart Assoc. 2019;8:e013405.","journal-title":"J Am Heart Assoc"},{"key":"2443_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/rheumatology\/ken078","volume":"47","author":"ME Hettema","year":"2008","unstructured":"Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology (Oxford). 2008;47:578\u201383.","journal-title":"Rheumatology (Oxford)"},{"key":"2443_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/art.30283","volume":"63","author":"MY Mok","year":"2011","unstructured":"Mok MY, Lau CS, Chiu SS, Tso AW, Lo Y, Law LS, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum. 2011;63:1387\u201395.","journal-title":"Arthritis Rheum"},{"key":"2443_CR22","first-page":"199","volume":"21","author":"NA Zakopoulos","year":"2003","unstructured":"Zakopoulos NA, Kotsis VT, Gialafos EJ, Papamichael CM, Pitiriga V, Mitsibounas DN, et al. Systemic sclerosis is not associated with clinical or ambulatory blood pressure. Clin Exp Rheumatol. 2003;21:199\u2013204.","journal-title":"Clin Exp Rheumatol"},{"key":"2443_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","volume":"3","author":"D Saleheen","year":"2015","unstructured":"Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2443_CR24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/acr.22852","volume":"68","author":"G Ozen","year":"2016","unstructured":"Ozen G, Inanc N, Unal AU, Korkmaz F, Sunbul M, Ozmen M, et al. Subclinical atherosclerosis in systemic sclerosis: not less frequent than rheumatoid arthritis and not detected with cardiovascular risk indices. Arthritis Care Res (Hoboken). 2016;68:1538\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2443_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13075-018-1771-0","volume":"20","author":"S Panopoulos","year":"2018","unstructured":"Panopoulos S, Tektonidou M, Drosos AA, Liossis SN, Dimitroulas T, Garyfallos A, et al. Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Res Ther. 2018;20:267.","journal-title":"Arthritis Res Ther"},{"key":"2443_CR26","doi-asserted-by":"crossref","unstructured":"Quevedo-Abeledo JC, Sanchez-Perez H, Tejera-Segura B, de Armas-Rillo L, Armas-Gonzalez E, Machado JD, et al. Differences in HDL-cholesterol efflux capacity between patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2020.","DOI":"10.1002\/acr.24407"},{"key":"2443_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11883-015-0554-1","volume":"18","author":"A Bhatt","year":"2016","unstructured":"Bhatt A, Rohatgi A. HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep. 2016;18:2.","journal-title":"Curr Atheroscler Rep"},{"key":"2443_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2018.08.027","volume":"277","author":"L Munoz-Hernandez","year":"2018","unstructured":"Munoz-Hernandez L, Ortiz-Bautista RJ, Brito-Cordova G, Lozano-Arvizu F, Saucedo S, Perez-Mendez O, et al. Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes. Atherosclerosis. 2018;277:72\u20139.","journal-title":"Atherosclerosis."},{"key":"2443_CR29","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","volume":"44","author":"VD Steen","year":"2001","unstructured":"Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001;44:2828\u201335.","journal-title":"Arthritis Rheum"},{"key":"2443_CR30","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","volume":"43","author":"PJ Clements","year":"2000","unstructured":"Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheumatism. 2000;43:2445\u201354.","journal-title":"Arthritis Rheumatism"},{"key":"2443_CR31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10067-013-2235-1","volume":"32","author":"TF Marighela","year":"2013","unstructured":"Marighela TF, Genaro Pde S, Pinheiro MM, Szejnfeld VL, Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol. 2013;32:1037\u201344.","journal-title":"Clin Rheumatol"},{"key":"2443_CR32","doi-asserted-by":"crossref","unstructured":"Siegert E, March C, Otten L, Makowka A, Preis E, Buttgereit F, et al: Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. Nutrition. 2018;55\u201356:51\u201355.","DOI":"10.1016\/j.nut.2018.03.046"},{"key":"2443_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/ijerph7010325","volume":"7","author":"T Faresjo","year":"2010","unstructured":"Faresjo T, Faresjo A. To match or not to match in epidemiological studies--same outcome but less power. Int J Environ Res Public Health. 2010;7:325\u201332.","journal-title":"Int J Environ Res Public Health"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02443-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-021-02443-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02443-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T01:10:53Z","timestamp":1614042653000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02443-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02443-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-62920\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-62920\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-62920\/v3","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Committee at Hospital Universitario de Canarias and all subjects provided informed written consent (CARESHUC Study: 2016_86) from Hospital Universitario de Canarias (Spain) (Code 2015_06), and all subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"In this manuscript, individual patient data are not presented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}